Northern Trust Corp Purchases 160,572 Shares of Moderna, Inc. $MRNA

Key Points

• Northern Trust Corp increased its stake in Moderna by 5.4%, owning over 3.1 million shares valued at approximately $88.4 million.
• Research analysts currently have a consensus rating of "Hold" for Moderna stock, with an average target price set at $42.88.
• Moderna reported ($2.13) earnings per share for the last quarter, exceeding expectations, but still faced a significant revenue decline of 41.1% year-over-year.

Northern Trust Corp increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,119,626 shares of the company's stock after buying an additional 160,572 shares during the quarter. Northern Trust Corp owned 0.81% of Moderna worth $88,441,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Brooklyn Investment Group grew its holdings in Moderna by 161.6% during the first quarter. Brooklyn Investment Group now owns 2,035 shares of the company's stock worth $58,000 after buying an additional 1,257 shares in the last quarter. Freestone Capital Holdings LLC bought a new stake in Moderna during the first quarter worth $782,000. Knuff & Co LLC grew its stake in Moderna by 58.4% in the 1st quarter. Knuff & Co LLC now owns 6,140 shares of the company's stock valued at $174,000 after purchasing an additional 2,263 shares during the period. Cresset Asset Management LLC bought a new position in Moderna in the 1st quarter valued at $522,000. Finally, American Century Companies Inc. grew its stake in Moderna by 4.1% in the 1st quarter. American Century Companies Inc. now owns 46,449 shares of the company's stock valued at $1,317,000 after purchasing an additional 1,830 shares during the period. Institutional investors own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Bank of America reduced their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. Royal Bank Of Canada reduced their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. Citigroup assumed coverage on Moderna in a research note on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective for the company. Finally, Leerink Partners reduced their price objective on Moderna from $18.00 to $15.00 and set an "underperform" rating for the company in a research note on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Moderna has an average rating of "Hold" and a consensus price target of $42.88.

Moderna Stock Down 1.0%

MRNA traded down $0.25 during trading on Friday, reaching $24.22. 5,441,890 shares of the company were exchanged, compared to its average volume of 10,712,708. The company's 50-day moving average is $29.12 and its two-hundred day moving average is $28.89. The company has a market cap of $9.42 billion, a price-to-earnings ratio of -3.21 and a beta of 1.83. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $79.96.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The business had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company's quarterly revenue was down 41.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.33) EPS. Moderna has set its FY 2025 guidance at EPS. Equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.